IP Verse

Linkage Modified Gapped Oligomeric Compounds And Uses Thereof - EP2742135

The patent EP2742135 was granted to Ionis Pharmaceuticals on Jun 10, 2020. The application was originally filed on Aug 8, 2012 under application number EP12748812A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2742135

IONIS PHARMACEUTICALS
Application Number
EP12748812A
Filing Date
Aug 8, 2012
Status
Patent Maintained As Amended
May 8, 2020
Grant Date
Jun 10, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ROCHEFeb 2, 2018D YOUNGWITHDRAWN

Patent Citations (99) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20070989574-
DESCRIPTIONUS20080026995-
DESCRIPTIONUS20080026998-
DESCRIPTIONUS20080056564-
DESCRIPTIONUS20080086231-
DESCRIPTIONUS20080097787-
DESCRIPTIONUS20080099844-
DESCRIPTIONUS20080129154-
DESCRIPTIONWO2008US64591-
DESCRIPTIONWO2008US66154-
DESCRIPTIONWO2008US68922-
DESCRIPTIONUS2002058802
DESCRIPTIONUS2003158403
DESCRIPTIONUS2004116687
DESCRIPTIONUS2004171570
DESCRIPTIONUS2005130923
DESCRIPTIONUS2007287831
DESCRIPTIONUS2008039618
DESCRIPTIONUS3687808
DESCRIPTIONUS4469863
DESCRIPTIONUS4845205
DESCRIPTIONUS5023243
DESCRIPTIONUS5130302
DESCRIPTIONUS5134066
DESCRIPTIONUS5175273
DESCRIPTIONUS5177198
DESCRIPTIONUS5223618
DESCRIPTIONUS5256775
DESCRIPTIONUS5264423
DESCRIPTIONUS5264562
DESCRIPTIONUS5264564
DESCRIPTIONUS5286717
DESCRIPTIONUS5366878
DESCRIPTIONUS5367066
DESCRIPTIONUS5378825
DESCRIPTIONUS5386023
DESCRIPTIONUS5432272
DESCRIPTIONUS5434257
DESCRIPTIONUS5457187
DESCRIPTIONUS5459255
DESCRIPTIONUS5476925
DESCRIPTIONUS5484908
DESCRIPTIONUS5489677
DESCRIPTIONUS5502177
DESCRIPTIONUS5508270
DESCRIPTIONUS5525711
DESCRIPTIONUS5552540
DESCRIPTIONUS5587469
DESCRIPTIONUS5594121
DESCRIPTIONUS5596091
DESCRIPTIONUS5602240
DESCRIPTIONUS5610289
DESCRIPTIONUS5614617
DESCRIPTIONUS5625050
DESCRIPTIONUS5645985
DESCRIPTIONUS5646269
DESCRIPTIONUS5681941
DESCRIPTIONUS5750692
DESCRIPTIONUS5763588
DESCRIPTIONUS5830653
DESCRIPTIONUS6005096
DESCRIPTIONUS6268490
DESCRIPTIONUS6426220
DESCRIPTIONUS6525191
DESCRIPTIONUS6670461
DESCRIPTIONUS6693187
DESCRIPTIONUS6770748
DESCRIPTIONUS6794499
DESCRIPTIONUS7034133
DESCRIPTIONUS7053207
DESCRIPTIONUS7399845
DESCRIPTIONUS7427672
DESCRIPTIONUS7569686
DESCRIPTIONWO0236743
DESCRIPTIONWO2004106356
DESCRIPTIONWO2005021570
DESCRIPTIONWO2007090071
DESCRIPTIONWO2007134181
DESCRIPTIONWO2008101157
DESCRIPTIONWO2008150729
DESCRIPTIONWO2008154401
DESCRIPTIONWO2009006478
DESCRIPTIONWO2009135322
DESCRIPTIONWO2009143369
DESCRIPTIONWO2010036698
DESCRIPTIONWO2010077578
DESCRIPTIONWO2011115818
DESCRIPTIONWO9402499
DESCRIPTIONWO9414226
DESCRIPTIONWO9417093
INTERNATIONAL-SEARCH-REPORTUS2005054600
INTERNATIONAL-SEARCH-REPORTUS6624293
INTERNATIONAL-SEARCH-REPORTWO9514030
INTERNATIONAL-SEARCH-REPORTWO9746570
OPPOSITIONWO2005023995
OPPOSITIONWO2007146511
OPPOSITIONWO2008049085
OPPOSITIONWO2013022984
OPPOSITIONWO9849349

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- EGLI MARTIN ET AL, "Insights from crystallographic studies into the structural and pairing properties of nucleic acid analogs and chemically modified DNA and RNA oligonucleotides", ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, (2007), vol. 36, ISSN 1056-8700, pages 281 - 305-
EXAMINATION- HERDEWIJN P, "Targeting RNA with Conformationally Restricted Oligonucleotides", LIEBIGS ANNALEN: ORGANIC AND BIOORGANIC CHEMISTRY, VCH PUBLISHERS, US, (19960901), no. 9, ISSN 0947-3440, pages 1337 - 1348, XP002094305-
EXAMINATION- OSTERGAARD MICHAEL E ET AL, "Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS", NUCLEIC ACIDS RESEARCH, (201311), vol. 41, no. 21, doi:doi:10.1093/nar/gkt725, ISSN 0305-1048(print), pages 9634 - 9650, XP055270067
OPPOSITION- "Chapter 12", Stanley T. CROOKE, Antisense Drug Technology, (20080000), pages 327 - 363, ISBN 9780849387968, XP055461184-
OPPOSITION- "Chapter 1", Stanley T. CROOKE, Antisense Drug Technology, (20080000), vol. 1, pages 1 - 46, ISBN 9780849387968, XP055461210-
OPPOSITION- "Chapter 6", Stanley T. CROOKE, Antisense Drug Technology, (20080000), vol. 6, pages 143 - 182, ISBN 9780849387968, XP055461203-
OPPOSITION- ELLEMANN NIELSEN et al., "α-L-LNA (α-L-ribo Configured Locked Nucleic Acid) Recognition of DNA: An NMR Spectroscopic Study", Chem. Eur. J., (20020000), vol. 8, no. 13, pages 3001 - 3009, XP002554919-
OPPOSITION- FURDON et al., "RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds.", NAR, (19890000), vol. 17, no. 22, pages 9193 - 9204, XP002924966-
OPPOSITION- KOCH et al., "Quantum Mechanical Studies of DNA and LNA", Nucleic Acid Therapeutics, (20140000), vol. 24, no. 2, pages 139 - 148, XP055366884-
OPPOSITION- Miho Takagi-Sato et al, "Fine-Tuning of ENA � Gapmers as Antisense Oligonucleotides for Sequence-Specific Inhibition", OLIGONUCLEOTIDES, (20070901), vol. 17, no. 3, pages 291 - 301-
OPPOSITION- QUARTIN et al., "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates", NAR, (19890000), vol. 17, no. 18, pages 7253 - 7262, XP000574936-
OPPOSITION- HAGEDORN et al., "Locked nucleic acid: modality, diversity, and drug discovery.", Drug Discovery Today, (20180000), vol. 23, no. 1, pages 101 - 114, XP055461215
OPPOSITION- ROBERTS et al., "Efficient and Persistent Splice Switching by Systemically Delivered LNA Oligonucleotides in Mice", Molecular therapy, (20060000), vol. 14, no. 4, pages 471 - 475, XP005644830
OPPOSITION- STEIN, "Is irrelevant cleavage the price of antisense efficacy?", Pharmacology & Therapeutics, (20000000), vol. 85, pages 231 - 236, XP027449632
OPPOSITION- WILDS et al., "Duplex recognition by oligonucleotides containing 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxy-2'-fluoro-D-ribose. Intermolecular 2'-OH-phosphate contacts versus sugar puckering in the stabilization of triple helical complexes", Bioconjugate Chem, (19990000), vol. 10, pages 299 - 305, XP002471775
OPPOSITION- PETERSEN et al., "Locked Nucleic Acid (LNA) Recognition of RNA: NMR Solution Structures of LNA:RNA Hybrids", J. Am. Chem. Soc., (20020000), vol. 124, pages 5974 - 5982, XP055035398
OPPOSITION- PALLAN et al., "A conformational transition in the structure of a 2′-thiomethyl-modified DNA visualized at high resolution", Chem Commun (Camb.), (20090000), vol. 15, pages 2017 - 2019, XP055461191
OPPOSITION- FLUITER et al., "Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4′-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer", Mol. BioSyst., (20090000), vol. 5, pages 838 - 843, XP055000711
OPPOSITION- AGRAWAL et al., "Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.", PNAS, (19900000), vol. 87, pages 1401 - 1405, XP002910161
OPPOSITION- T AKAGI-SATO, "Fine-Tuning of ENA Gapmers as Antisense Oligonucleotides for Sequence-Specific Inhibition", Oligonucleotides, (20070000), vol. 17, pages 291 - 301, XP055246491
OPPOSITION- KURRECK et al., "Design of antisense oligonucleotides stabilized by locked nucleic acids", NAR, (20020000), vol. 30, no. 9, pages 1911 - 1918, XP002281375
OPPOSITION- BUREL et al., "Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts", NAR, (20150000), vol. 44, no. 5, pages 2093 - 2109, XP055432549

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents